{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T04:10:37Z","timestamp":1730607037548,"version":"3.28.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,2]]},"DOI":"10.7759\/cureus.72878","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:13:13Z","timestamp":1730553193000},"source":"Crossref","is-referenced-by-count":0,"title":["Effective Management of Severe Epidermal Growth Factor Receptor Inhibitors-Induced Papulopustular Eruption With Low-Dose Isotretinoin and Corticosteroids"],"prefix":"10.7759","author":[{"given":"Beatrice","family":"B\u0103l\u0103ceanu-Gur\u0103u","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andra","family":"Copilau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Timofte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian-Dorin","family":"Gurau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara Madalina","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Cutaneous Adverse Reactions Associated With EGFR-inhibitors and Other Molecularly-targeted Skin Cancer Therapies","author":"Orzan OA","year":"2024","unstructured":"Orzan OA, Ion A, B\u0103l\u0103ceanu-Gur\u0103u B, et al.. Cutaneous Adverse Reactions Associated With EGFR-inhibitors and Other Molecularly-targeted Skin Cancer Therapies. Orzan OA (ed): KF&T Kft, Budapest, Hungary; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello F","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008, 358:1160-74. 10.1056\/NEJMra0707704","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst RS","year":"2004","unstructured":"Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004, 59:21-6. 10.1016\/j.ijrobp.2003.11.041","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-017-0050-6","article-title":"EGFR inhibitors and cutaneous complications: a practical approach to management","volume":"5","author":"Guggina LM","year":"2017","unstructured":"Guggina LM, Choi AW, Choi JN. EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther. 2017, 5:135-48. 10.1007\/s40487-017-0050-6","journal-title":"Oncol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153219","article-title":"The impact of long-term antibiotic therapy of cutaneous adverse reactions to EGFR inhibitors in colorectal cancer patients","volume":"10","author":"Mihai MM","year":"2021","unstructured":"Mihai MM, Ion A, Giurc\u0103neanu C, et al.. The impact of long-term antibiotic therapy of cutaneous adverse reactions to EGFR inhibitors in colorectal cancer patients. J Clin Med. 2021, 10:3219. 10.3390\/jcm10153219","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12276708","article-title":"Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition","volume":"85","author":"Green MR","year":"1985","unstructured":"Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol. 1985, 85:239-45. 10.1111\/1523-1747.ep12276708","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture ME","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006, 6:803-12. 10.1038\/nrc1970","journal-title":"Nat Rev Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch TJ Jr","year":"2007","unstructured":"Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007, 12:610-21. 10.1634\/theoncologist.12-5-610","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture ME","year":"2006","unstructured":"Lacouture ME, Lai SE. The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol. 2006, 155:852-4. 10.1111\/j.1365-2133.2006.07452.x","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2017.71106","article-title":"The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors","volume":"34","author":"Owczarek W","year":"2017","unstructured":"Owczarek W, S\u0142owi\u0144ska M, Lesiak A, et al.. The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. Postepy Dermatol Alergol. 2017, 34:418-28. 10.5114\/ada.2017.71106","journal-title":"Postepy Dermatol Alergol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture ME","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, et al.. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011, 19:1079-95. 10.1007\/s00520-011-1197-6","journal-title":"Support Care Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl409","article-title":"Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients","volume":"18","author":"Bossi P","year":"2007","unstructured":"Bossi P, Liberatoscioli C, Bergamini C, et al.. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol. 2007, 18:601-2. 10.1093\/annonc\/mdl409","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su X","year":"2009","unstructured":"Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009, 77:124-33. 10.1159\/000229752","journal-title":"Oncology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14756","article-title":"Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis","volume":"175","author":"Petrelli F","year":"2016","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol. 2016, 175:1166-74. 10.1111\/bjd.14756","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi A","year":"2009","unstructured":"Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009, 77:120-3. 10.1159\/000229751","journal-title":"Oncology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15170","article-title":"Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash","volume":"47","author":"Tohyama M","year":"2020","unstructured":"Tohyama M, Hamada M, Harada D, et al.. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash. J Dermatol. 2020, 47:121-7. 10.1111\/1346-8138.15170","journal-title":"J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15412","article-title":"A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors","volume":"35","author":"Bierbrier R","year":"2022","unstructured":"Bierbrier R, Lam M, Pehr K. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. Dermatol Ther. 2022, 35:e15412. 10.1111\/dth.15412","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.003","article-title":"A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions","volume":"82","author":"Andrews ED","year":"2020","unstructured":"Andrews ED, Garg N, Patel AB. A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions. J Am Acad Dermatol. 2020, 82:998-1000. 10.1016\/j.jaad.2019.10.003","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.090","article-title":"Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions","volume":"84","author":"Costello CM","year":"2021","unstructured":"Costello CM, Hill HE, Brumfiel CM, Yang YW, Swanson DL. Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions. J Am Acad Dermatol. 2021, 84:840-1. 10.1016\/j.jaad.2020.09.090","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/314351-effective-management-of-severe-epidermal-growth-factor-receptor-inhibitors-induced-papulopustular-eruption-with-low-dose-isotretinoin-and-corticosteroids","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:13:15Z","timestamp":1730553195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/314351-effective-management-of-severe-epidermal-growth-factor-receptor-inhibitors-induced-papulopustular-eruption-with-low-dose-isotretinoin-and-corticosteroids"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.72878","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,2]]}}}